drugset
drugset / Trial / NCT05471050

The Combination of Tacrolimus and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

NCT05471050 ↗

Phase 2 Unknown 120 enrolled Peking University People's Hospital
RandomizedParallel-groupOpen-labelTreatment

Summary

Randomized, open-label, multicenter study to compare the efficacy and safety of combination of tacrolimus and danazol versus danazol for the treatment of adults with steroid-resistant/relapse immune thrombocytopenia (ITP).

Timeline

Start
2022-03-02
Primary completion
2023-03-01
Completion
2023-06-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Danazol Other / unclassified 200 mg —
Subject Tacrolimus Small molecule 0.03 mg/kg —

Indications

autoimmune thrombocytopenia